Advisor Partners LLC reduced its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 35.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,721 shares of the biopharmaceutical company’s stock after selling 954 shares during the period. Advisor Partners LLC’s holdings in Alexion Pharmaceuticals were worth $209,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of ALXN. Guardian Life Insurance Co. of America raised its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. acquired a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $111,000. Independent Portfolio Consultants Inc. raised its position in Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 340 shares during the period. Huntington National Bank raised its position in Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares during the period. Finally, FUKOKU MUTUAL LIFE INSURANCE Co raised its position in Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 100 shares during the period. 90.74% of the stock is owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 132.93 on Monday. The company has a market capitalization of $29.67 billion, a P/E ratio of 57.65 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41. The company has a 50 day moving average of $129.36 and a 200-day moving average of $122.92.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.48. The company had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.13 EPS. On average, equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Advisor Partners LLC Lowers Position in Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/14/advisor-partners-llc-lowers-position-in-alexion-pharmaceuticals-inc-alxn.html.

Several research firms have recently commented on ALXN. UBS AG reaffirmed a “buy” rating and issued a $140.00 price target (down from $143.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, May 31st. BMO Capital Markets reissued an “outperform” rating and set a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, May 1st. SunTrust Banks, Inc. reissued a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Finally, BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals has an average rating of “Buy” and an average price target of $156.89.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The shares were bought at an average price of $116.32 per share, with a total value of $156,910,445.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders bought a total of 2,019,734 shares of company stock worth $235,606,846 in the last ninety days. Insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.